Literature DB >> 7475720

Telomerase activity in human brain tumours.

L A Langford1, M A Piatyszek, R Xu, S C Schold, J W Shay.   

Abstract

Malignant gliomas are invasive into surrounding brain and are refractory to therapy. Telomerase stabilises telomere length and may immortalise cells to allow unlimited proliferation. Our analysis of telomerase activity in 90 human gliomas showed that 19 of 19 oligodendrogliomas and 38 of 51 glioblastoma multiformes have detectable telomerase activity. The absence of telomerase activity in anaplastic astrocytomas (2/20 positive) and in one-quarter (13/51) of the glioblastomas suggests that these tumours follow different pathways of neoplastic progression. Thus we have found that a distinct subgroup of brain tumour consists of transformed yet pre-immortal cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7475720     DOI: 10.1016/s0140-6736(95)91865-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  45 in total

1.  A rapid, useful and quantitative method to measure telomerase activity by hybridization protection assay connected with a telomeric repeat amplification protocol.

Authors:  M Hirose; J Abe-Hashimoto; K Ogura; H Tahara; T Ide; T Yoshimura
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Telomerase expression in uveal melanoma.

Authors:  B Heine; S E Coupland; S Kneiff; G Demel; N Bornfeld; M Hummel; H Stein
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

3.  Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status.

Authors:  Hideaki Ito; Takao Kanzawa; Toru Miyoshi; Satoshi Hirohata; Satoru Kyo; Arifumi Iwamaru; Hiroshi Aoki; Yasuko Kondo; Seiji Kondo
Journal:  Hum Gene Ther       Date:  2005-06       Impact factor: 5.695

4.  Telomerase expression in intracranial tumours: prognostic potential for malignant gliomas and meningiomas.

Authors:  M L Falchetti; R Pallini; L M Larocca; R Verna; E D'Ambrosio
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

5.  Telomerase activity in gestational trophoblastic disease.

Authors:  A N Cheung; D K Zhang; Y Liu; H Y Ngan; D H Shen; S W Tsao
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

6.  TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.

Authors:  Matthias Simon; Ismail Hosen; Konstantinos Gousias; Sivaramakrishna Rachakonda; Barbara Heidenreich; Marco Gessi; Johannes Schramm; Kari Hemminki; Andreas Waha; Rajiv Kumar
Journal:  Neuro Oncol       Date:  2014-08-18       Impact factor: 12.300

7.  Molecular targeting of neural cancer stem cells: TTAGGG, you're it!

Authors:  Anita B Hjelmeland; Jeremy N Rich
Journal:  Clin Cancer Res       Date:  2011-01-01       Impact factor: 12.531

8.  Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors.

Authors:  Zachary J Reitman; Christopher J Pirozzi; Hai Yan
Journal:  Acta Neuropathol       Date:  2013-12       Impact factor: 17.088

9.  RNA interference mediated downregulation of human telomerase reverse transcriptase (hTERT) in LN18 cells.

Authors:  Ch Lavanya; M K Sibin; M M Srinivas Bharath; M Jeru Manoj; Manjunatha M Venkataswamy; Dhananjaya I Bhat; K V L Narasinga Rao; G K Chetan
Journal:  Cytotechnology       Date:  2016-10-18       Impact factor: 2.058

10.  Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts.

Authors:  Tomoko Ozawa; Sergei M Gryaznov; Lily J Hu; Krisztina Pongracz; Raquel A Santos; Andrew W Bollen; Kathleen R Lamborn; Dennis F Deen
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.